Targeting complex interactions in diverse clinical ecosystems
Our discovery engine has led to impactful therapies that change disease progression across several clinical modalities:
In commercial development
Synedgen’s wound care products, SynePure™ Wound Rinse and Catasyn™ Advanced Technology Wound Hydrogel, are currently in commercialization stages and will soon be available for purchase in the U.S. through our partners.
Synedgen’s therapies provide relief from gastrointestinal side effects of cancer radiation therapy and are in early stages of product development.
In research and development
Synedgen has recently completed pilot clinical trials for its sinus health product. This portfolio is being developed for acute and chronic rhinosinusitis.
Synedgen has been awarded a 3 year grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to develop molecules intended to counteract severe, ulcerative eye injury.